BI 456906
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist from Boehringer Ingelheim and Zealand, currently in late-stage trials for obesity and MASH. Phase 2 data showed roughly 19% body-weight loss at the highest dose over 46 weeks, which is genuinely strong, but it is not yet approved and all human data comes from company-run trials. It is one of the most-searched grey-market fat-loss compounds despite no regulatory sign-off.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published start, titration steps, and target dose, shown as reference. Included with membership.
Reference values as published in the research record — not a recommendation, instruction, or dose suggestion for any person. Not medical advice.
The live calculator — enter any vial size, diluent volume, and syringe size to see the draw computed — is included with membership.